GRAd-COV2

BIOLOGICAL2 trials

Sponsors

ReiThera Srl

Conditions

COVID-19Covid19

Phase 1

Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine

CompletedNCT04528641

ReiThera SrlCOVID-19

Start: 2020-08-10End: 2021-05-19Updated: 2022-02-08

Phase 2

Study of GRAd-COV2 for the Prevention of COVID-19 in Adults

CompletedNCT04791423

ReiThera SrlCovid19

Start: 2021-03-15End: 2022-05-13Updated: 2023-03-29

Related Papers

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.

2023-05-298 citations

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Molecular Therapy2021-04-2357 citations